Lunai Bioworks Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.3M
- Price
- $1.18
- % Change (Daily % change from the live per-ticker quote feed.)
- -9.23%
- Volume
- 54.7K
About
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
Quick stats
Shares outstanding4.5M
Computed float3.1M
Float / shares68.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001527728
AI Summary
AI-generated1/24
minorbullishpartnership
Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement
Lunai Bioworks signed an exclusive worldwide license and collaboration agreement with Tanaist, adding human cellular phenotyping to its AI-driven Parkinson's disease discovery platform.
The deal gives Lunai exclusive rights to Tanaist's cellular phenotyping technology in the Parkinson's field to test whether its three identified patient subtypes -- derived from analysis of more than 650 PPMI participants and 4,500+ proteomic probes -- reproduce across independent cohorts and map to distinct cellular mechanisms.
Lunai will own collaboration-generated analyses, biomarker findings and IP, while Tanaist retains ownership of its underlying platform. No financial terms were disclosed.
The partnership follows an August 2026 collaboration with BrainStorm Therapeutics as Lunai builds multiple validation paths toward biomarker and therapeutic target development.
Red flags
- no financial terms disclosed for the exclusive license
- early-stage research collaboration with risks in reproducing computational findings in cellular systems (per company's own forward-looking statement caveats)